MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
January 04 2021 - 5:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat at the H.C.
Wainwright Bioconnect 2021 Conference which will be available on
demand starting on January 11, 2021 at 6:00 am (ET). Interested
parties can access a link to the on demand webcast of the
presentation from the Events & Presentations section of the
Company's website at http://www.mannkindcorp.com. The webcast
replay will remain available for 14 days following the live
presentation.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake Village,
California, and has a state-of-the art manufacturing facility in
Danbury, Connecticut. The Company also employs field sales and
medical representatives across the U.S. For further information,
visit www.mannkindcorp.com.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024